123 related articles for article (PubMed ID: 30712391)
1. Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials.
Birkhaeuser M; Bitzer J; Braat S; Ramos Y
Climacteric; 2019 Jun; 22(3):312-322. PubMed ID: 30712391
[TBL] [Abstract][Full Text] [Related]
2. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
Hattersley G; Harris AG; Simon JA; Constantine GD
Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Pinkerton JV; Constantine G; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
[TBL] [Abstract][Full Text] [Related]
4. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.
Hitchcock CL; Prior JC
Menopause; 2012 Aug; 19(8):886-93. PubMed ID: 22453200
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
[TBL] [Abstract][Full Text] [Related]
7. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
[TBL] [Abstract][Full Text] [Related]
8. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
9. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
[TBL] [Abstract][Full Text] [Related]
12. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
Simon JA;
Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.
Ivgy-May N; Hajak G; van Osta G; Braat S; Chang Q; Roth T
J Clin Sleep Med; 2020 Sep; 16(9):1455-1467. PubMed ID: 32351205
[TBL] [Abstract][Full Text] [Related]
14. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
[TBL] [Abstract][Full Text] [Related]
15. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
Simon JA; Portman DJ; Kaunitz AM; Mekonnen H; Kazempour K; Bhaskar S; Lippman J
Menopause; 2013 Oct; 20(10):1027-35. PubMed ID: 24045678
[TBL] [Abstract][Full Text] [Related]
16. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
Cohen LS; Joffe H; Guthrie KA; Ensrud KE; Freeman M; Carpenter JS; Learman LA; Newton KM; Reed SD; Manson JE; Sternfeld B; Caan B; Freeman EW; LaCroix AZ; Tinker LF; Booth-Laforce C; Larson JC; Anderson GL
Menopause; 2014 Apr; 21(4):347-54. PubMed ID: 23982113
[TBL] [Abstract][Full Text] [Related]
18. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
Simon JA; Gaines T; LaGuardia KD;
Menopause; 2016 Nov; 23(11):1214-1221. PubMed ID: 27760081
[TBL] [Abstract][Full Text] [Related]
19. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
20. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
Rowan JP; Simon JA; Speroff L; Ellman H
Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
